These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8110062)

  • 1. Alprostadil: an effective antiplatelet agent for calves.
    Jaarsma RL; Mohammad SF; Burns GL; Olsen DB
    Artif Organs; 1993 Nov; 17(11):935-9. PubMed ID: 8110062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the antiplatelet effect of aspirin on human and bovine platelets.
    Swier P; Mohammad SF; Olsen DB; Kolff WJ
    ASAIO Trans; 1989; 35(3):205-8. PubMed ID: 2597445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
    Yu SM; Chen CC; Ko FN; Huang YL; Huang TF; Teng CM
    Biochem Pharmacol; 1992 Jan; 43(2):323-9. PubMed ID: 1310852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species.
    Nishio S; Matsuura H; Kanai N; Fukatsu Y; Hirano T; Nishikawa N; Kameoka K; Umetsu T
    Jpn J Pharmacol; 1988 May; 47(1):1-10. PubMed ID: 2842529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
    Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of TFC-612, a 7-thia prostaglandin E1 derivative, on platelet function.
    Motoyama Y; Sakata Y; Seki J; Asada T; Namikawa Y; Horiai H; Ono T
    Thromb Res; 1991 Jul; 63(1):29-38. PubMed ID: 1658963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of TFC-612, a 7-THIA prostaglandin E1 derivative, on platelet function.
    Motoyama Y; Sakata Y; Seki J; Asada T; Namikawa Y; Horiai H; Ono T
    Thromb Res; 1991 Jun; 62(5):471-80. PubMed ID: 1654599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. W1, a Novel Oral Antiplatelet Agent With Less Resistance Than Clopidogrel.
    Ge P; Du L; Han C; Li H; Feng Y; Han J; Wang Z; Xiong L; Yuan M; Liu Y
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):110-117. PubMed ID: 27930430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
    Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
    Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intracellular actions of antiplatelet drugs which affect cyclic AMP metabolism in platelets--their effects on Ca2+ mobilization and protein phosphorylation in human platelets].
    Nishikawa M; Saitoh M; Deguchi K; Shirakawa S
    Rinsho Byori; 1990 Jul; Suppl 86():54-61. PubMed ID: 2172597
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of aspirin and carbacyclin on bovine platelet function.
    Rao GH; Ericson DG; Weiss DJ; Parks PG; White JG
    ASAIO J; 1992; 38(4):830-4. PubMed ID: 1450481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between prostaglandin E1 and nitric oxide (NO).
    Katzenschlager R; Weiss K; Rogatti W; Stelzeneder M; Sinzinger H
    Thromb Res; 1991 May; 62(4):299-304. PubMed ID: 1866712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of prostaglandin E1 during preparation of platelet concentrates.
    Hawker RJ; Turner VS; Mitchell SG
    Transfus Med; 1996 Sep; 6(3):249-54. PubMed ID: 8885155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH; Tzeng CC; Teng CM
    Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A; Michael-Hepp J; Meyer J; Darius H
    Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
    Terres W; Beythien C; Kupper W; Bleifeld W
    Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.